About

EpiVax is a biotechnology company based in Providence, RI that is dedicated to supporting the pharmaceutical and biotechnology industries in developing safe and effective vaccines and biologics. We partner to aid in developing products that will afford better safety and efficacy outcomes through the application of our cutting-edge immunoinformatics and in vitro immunogenicity assessment tools and techniques. We strive to see beyond the horizon, desiring to be a part of an effort that is larger than ourselves – improving human health everywhere. EpiVax utilizes its scientific and technological assets related to T cell-driven immunogenicity, epitope discovery, de-immunization, and vaccine design through a mix of collaborative and internal programs. We have established collaborations and long-standing business relationships with pharmaceutical, vaccine, and biotechnology companies to provide support for superior product development from discovery to patient. EpiVax’s team of immunogenicity experts continuously conduct internal discovery and development efforts to maintain leadership and high-caliber expertise in the field of immunogenicity.